In consultation: Guidance and quality standards
Showing 1 to 2 of 2
Title | Consultation | Type | Consultation end date |
---|---|---|---|
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Draft guidance | Technology appraisal guidance | |
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981 | Draft guidance | Technology appraisal guidance |